Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Corrigendum to "Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands" [Canc. Lett. 403 (2017) 98-107].

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2018 Sep 1;431:247. doi: 10.1016/j.canlet.2018.06.022. Epub 2018 Jun 19. No abstract available.

PMID:
29934232
2.

Hypoxia modulates CCR7 expression in head and neck cancers.

Basheer HA, Pakanavicius E, Cooper PA, Shnyder SD, Martin L, Hunter KD, Vinader V, Afarinkia K.

Oral Oncol. 2018 May;80:64-73. doi: 10.1016/j.oraloncology.2018.03.014. Epub 2018 Apr 4.

PMID:
29706190
3.

Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2017 Sep 10;403:98-107. doi: 10.1016/j.canlet.2017.04.041. Epub 2017 Jun 15. Erratum in: Cancer Lett. 2018 Sep 1;431:247.

PMID:
28624622
4.

RGD-Binding Integrins in Head and Neck Cancers.

Ahmedah HT, Patterson LH, Shnyder SD, Sheldrake HM.

Cancers (Basel). 2017 May 26;9(6). pii: E56. doi: 10.3390/cancers9060056. Review.

5.

Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines.

Ahmed M, Basheer HA, Ayuso JM, Ahmet D, Mazzini M, Patel R, Shnyder SD, Vinader V, Afarinkia K.

Sci Rep. 2017 Apr 21;7(1):1075. doi: 10.1038/s41598-017-00949-4.

6.

Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents.

Rossington SB, Hadfield JA, Shnyder SD, Wallace TW, Williams KJ.

Bioorg Med Chem. 2017 Mar 1;25(5):1630-1642. doi: 10.1016/j.bmc.2017.01.027. Epub 2017 Jan 19.

PMID:
28143677
7.

The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models.

Hussain N, Connah D, Ugail H, Cooper PA, Falconer RA, Patterson LH, Shnyder SD.

Sci Rep. 2016 Aug 5;6:31136. doi: 10.1038/srep31136.

8.

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

Ross RL, McPherson HR, Kettlewell L, Shnyder SD, Hurst CD, Alder O, Knowles MA.

BMC Cancer. 2016 Jul 28;16:553. doi: 10.1186/s12885-016-2570-0.

9.

Use of the Hollow Fiber Assay to Evaluate Agents That Target the Tumor Neovasculature.

Cooper PA, Shnyder SD.

Methods Mol Biol. 2016;1430:375-86. doi: 10.1007/978-1-4939-3628-1_26.

PMID:
27172968
10.

The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics.

Grant CA, Twigg PC, Saeed RF, Lawson G, Falconer RA, Shnyder SD.

Bionanoscience. 2016;6:81-84. Epub 2016 Jan 25.

11.

Study of the Chemotactic Response of Multicellular Spheroids in a Microfluidic Device.

Ayuso JM, Basheer HA, Monge R, Sánchez-Álvarez P, Doblaré M, Shnyder SD, Vinader V, Afarinkia K, Fernández LJ, Ochoa I.

PLoS One. 2015 Oct 7;10(10):e0139515. doi: 10.1371/journal.pone.0139515. eCollection 2015.

13.

Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells.

van Rijt SH, Romero-Canelón I, Fu Y, Shnyder SD, Sadler PJ.

Metallomics. 2014 May;6(5):1014-22. doi: 10.1039/c4mt00034j.

PMID:
24668459
14.

Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA.

Mol Pharm. 2014 Apr 7;11(4):1294-300. doi: 10.1021/mp400760b. Epub 2014 Mar 27.

PMID:
24641451
15.

Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration.

Al-Saraireh YM, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, Loadman PM, Errington RJ, Smith PJ, Fukuda M, Gerardy-Schahn R, Patterson LH, Shnyder SD, Falconer RA.

PLoS One. 2013 Aug 9;8(8):e73366. doi: 10.1371/journal.pone.0073366. eCollection 2013.

16.

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K.

J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26.

PMID:
23844629
17.

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC.

Cancer Discov. 2013 Sep;3(9):1058-71. doi: 10.1158/2159-8290.CD-12-0569. Epub 2013 Jun 6.

18.

NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7.

Smith PJ, Furon E, Wiltshire M, Chappell S, Patterson LH, Shnyder SD, Falconer RA, Errington RJ.

Cytometry A. 2013 Jul;83(7):659-71. doi: 10.1002/cyto.a.22306. Epub 2013 May 28.

19.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M.

Clin Cancer Res. 2013 Jun 1;19(11):2952-61. doi: 10.1158/1078-0432.CCR-13-0238. Epub 2013 Apr 15.

20.

Non-invasive molecular imaging for preclinical cancer therapeutic development.

O'Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH.

Br J Pharmacol. 2013 Jun;169(4):719-35. doi: 10.1111/bph.12155. Review.

21.

Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties.

Cosentino L, Redondo-Horcajo M, Zhao Y, Santos AR, Chowdury KF, Vinader V, Abdallah QM, Abdel-Rahman H, Fournier-Dit-Chabert J, Shnyder SD, Loadman PM, Fang WS, Díaz JF, Barasoain I, Burns PA, Pors K.

J Med Chem. 2012 Dec 27;55(24):11062-6. doi: 10.1021/jm301151t. Epub 2012 Dec 7.

PMID:
23176628
22.

Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation.

Fournier-Dit-Chabert J, Vinader V, Santos AR, Redondo-Horcajo M, Dreneau A, Basak R, Cosentino L, Marston G, Abdel-Rahman H, Loadman PM, Shnyder SD, Díaz JF, Barasoain I, Falconer RA, Pors K.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7693-6. doi: 10.1016/j.bmcl.2012.09.104. Epub 2012 Oct 10.

PMID:
23103097
23.

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH.

Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1.

24.

Polysialyltransferase: a new target in metastatic cancer.

Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH.

Curr Cancer Drug Targets. 2012 Oct;12(8):925-39. Review.

PMID:
22463390
25.

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Sutherland M, Gordon A, Shnyder SD, Patterson LH, Sheldrake HM.

Cancers (Basel). 2012 Oct 26;4(4):1106-45. doi: 10.3390/cancers4041106.

26.

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH.

Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14.

PMID:
22002321
27.

The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.

Burns CJ, Fantino E, Powell AK, Shnyder SD, Cooper PA, Nelson S, Christophi C, Malcontenti-Wilson C, Dubljevic V, Harte MF, Joffe M, Phillips ID, Segal D, Wilks AF, Smith GD.

J Pharmacol Exp Ther. 2011 Dec;339(3):799-806. doi: 10.1124/jpet.111.186965. Epub 2011 Sep 14.

28.

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.

Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.

Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43. Epub 2011 Aug 12.

PMID:
21836632
29.

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30.

PMID:
21569858
30.

Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.

Prokopiou EM, Cooper PA, Pettit GR, Bibby MC, Shnyder SD.

Mol Med Rep. 2010 Mar-Apr;3(2):309-13. doi: 10.3892/mmr_00000256.

PMID:
21472238
31.

An agarose spot chemotaxis assay for chemokine receptor antagonists.

Vinader V, Al-Saraireh Y, Wiggins HL, Rappoport JZ, Shnyder SD, Patterson LH, Afarinkia K.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):213-6. doi: 10.1016/j.vascn.2011.01.004. Epub 2011 Feb 1.

PMID:
21292017
32.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA.

Br J Cancer. 2011 Jan 4;104(1):75-82. doi: 10.1038/sj.bjc.6606016. Epub 2010 Nov 30.

33.

Organometallic osmium arene complexes with potent cancer cell cytotoxicity.

Fu Y, Habtemariam A, Pizarro AM, van Rijt SH, Healey DJ, Cooper PA, Shnyder SD, Clarkson GJ, Sadler PJ.

J Med Chem. 2010 Nov 25;53(22):8192-6. doi: 10.1021/jm100560f. Epub 2010 Oct 26.

PMID:
20977192
34.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.

Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27.

35.

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD.

Gene Ther. 2010 Aug;17(8):1000-10. doi: 10.1038/gt.2010.45. Epub 2010 Apr 22.

36.

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.

Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, Telfer BA, Dunk CR, Harris PA, Stratford IJ.

Mol Cancer Ther. 2009 Dec;8(12):3266-75. doi: 10.1158/1535-7163.MCT-09-0396.

37.

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.

Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA.

Cancer Res. 2009 Jun 1;69(11):4613-20. doi: 10.1158/0008-5472.CAN-08-2816. Epub 2009 May 19.

38.

Use of the hollow fibre assay for studies of tumor neovasculature.

Shnyder SD.

Methods Mol Biol. 2009;467:331-42.

PMID:
19301682
39.

Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer.

Shnyder SD, Mangum JE, Hubbard MJ.

J Proteome Res. 2008 Aug;7(8):3364-72. doi: 10.1021/pr800126n. Epub 2008 Jul 4.

PMID:
18598068
40.

Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity.

Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kühnle M, Gerspach J, Sterns T, Shnyder SD, Gill JH, Männel DN, Pfizenmaier K, Scheurich P.

J Immunol. 2008 Jun 15;180(12):8176-83.

41.

Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv.

Stavri M, Mathew KT, Gordon A, Shnyder SD, Falconer RA, Gibbons S.

Phytochemistry. 2008 Jun;69(9):1915-8. doi: 10.1016/j.phytochem.2008.03.012. Epub 2008 Apr 28.

PMID:
18448140
42.

Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model.

Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC.

J Nat Prod. 2008 Mar;71(3):321-4. Epub 2007 Dec 22.

PMID:
18154271
43.

Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.

Seville S, Phillips RM, Shnyder SD, Wright CW.

Bioorg Med Chem. 2007 Oct 1;15(19):6353-60. Epub 2007 Jul 6.

PMID:
17643990
44.

Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.

Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC.

Int J Oncol. 2007 Aug;31(2):353-60.

PMID:
17611692
45.

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.

Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH.

J Med Chem. 2006 Nov 30;49(24):7013-23.

PMID:
17125254
46.

The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

Suggitt M, Cooper PA, Shnyder SD, Bibby MC.

Int J Oncol. 2006 Dec;29(6):1493-9.

PMID:
17088988
47.

Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.

Wells G, Martin CR, Howard PW, Sands ZA, Laughton CA, Tiberghien A, Woo CK, Masterson LA, Stephenson MJ, Hartley JA, Jenkins TC, Shnyder SD, Loadman PM, Waring MJ, Thurston DE.

J Med Chem. 2006 Sep 7;49(18):5442-61.

PMID:
16942018
48.

Reducing the cost of screening novel agents using the hollow fibre assay.

Shnyder SD, Cooper PA, Scally AJ, Bibby MC.

Anticancer Res. 2006 May-Jun;26(3A):2049-52.

49.

Heparin octasaccharides inhibit angiogenesis in vivo.

Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC.

Clin Cancer Res. 2005 Nov 15;11(22):8172-9.

50.

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC.

Anticancer Res. 2005 May-Jun;25(3B):1889-94.

Supplemental Content

Loading ...
Support Center